Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Quince Therapeutics (QNCX)
NASDAQ:QNCX
Holding QNCX?
Track your performance easily
QNCX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.51 - $1.79
Previous Close$1.4
Volume149.25K
Average Volume (3M)545.58K
Market Cap
$66.21M
Enterprise Value$28.95M
Total Cash (Recent Filing)$51.55M
Total Debt (Recent Filing)$14.29M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Mar 04, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding43,276,606
10 Day Avg. Volume2,504,293
30 Day Avg. Volume545,580
Standard Deviation0.33
R-Squared0.01
Alpha0.00537
Financial Highlights & Ratios
Price to Book (P/B)1.34
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.54
Forecast
1Y Price Target
$11.50Price Target Upside687.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Quince Therapeutics News
PremiumCompany Announcements
Quince Therapeutics Appoints Rajiv Patni to Board of Directors
PremiumCompany Announcements
Quince Therapeutics Executive Compensation and Stock Option UpdateOwnership Overview
18.39% Insiders
3.73% Mutual Funds
0.12% Other Institutional Investors
74.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
QNCX FAQ
What was Quince Therapeutics’s price range in the past 12 months?
Quince Therapeutics lowest stock price was $0.51 and its highest was $1.79 in the past 12 months.
What is Quince Therapeutics’s market cap?
Currently, no data Available
When is Quince Therapeutics’s upcoming earnings report date?
Quince Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 117 days.
How were Quince Therapeutics’s earnings last quarter?
Quince Therapeutics released its earnings results on Aug 13, 2024. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.65.
Is Quince Therapeutics overvalued?
According to Wall Street analysts Quince Therapeutics’s price is currently Undervalued.
Does Quince Therapeutics pay dividends?
Quince Therapeutics does not currently pay dividends.
What is Quince Therapeutics’s EPS estimate?
Quince Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Quince Therapeutics have?
Quince Therapeutics has 43,276,608 shares outstanding.
What happened to Quince Therapeutics’s price movement after its last earnings report?
Quince Therapeutics reported an EPS of -$0.65 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.172%.
Which hedge fund is a major shareholder of Quince Therapeutics?
Currently, no hedge funds are holding shares in QNCX
---
Quince Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.50 (687.67% Upside)
$11.50 (687.67% Upside)
Blogger Sentiment
Bullish
QNCX Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $163.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.08%
12-Months-Change
Fundamentals
Return on Equity
-79.38%
Trailing 12-Months
Asset Growth
51.77%
Trailing 12-Months
Company Description
Quince Therapeutics
Cortexyme, Inc. is a biopharmaceutical company, which develops therapeutics based on data supporting a new theory of the cause of Alzheimer's and other neurodegenerative disorders. Its product, COR388, is in clinical trial. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.
---
QNCX Stock 12 Month Forecast
Average Price Target
$11.50
▲(687.67% Upside)
Technical Analysis
Best Analysts Covering QNCX
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+80.00%
initiated a buy rating 17 days ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +80.00% per trade.
---